GH
- Guardant Health, Inc.
()
Overview
Company Summary
Guardant Health, Inc. is a healthcare company that specializes in developing and commercializing advanced diagnostic solutions to improve cancer treatment. Their primary focus is on liquid biopsy technology, which involves the analysis of a patient's blood sample to detect and monitor cancer-related genomic alterations.
Guardant Health's flagship product is the Guardant360, a comprehensive genomic profiling test that helps oncologists make informed treatment decisions based on a patient's unique cancer biomarkers. This test can detect alterations in over 70 cancer-related genes, allowing physicians to personalize treatment plans and monitor disease progression more effectively.
By utilizing next-generation sequencing and other molecular technologies, Guardant Health aims to overcome the limitations of traditional tissue biopsies, which can be invasive, time-consuming, and may not always provide sufficient tumor information. The company's liquid biopsy solutions offer a non-invasive and more comprehensive approach to cancer diagnostics, enabling early detection, therapeutic selection, and monitoring of treatment response.
Beyond their core product, Guardant Health has expanded its portfolio to include other precision oncology solutions. This includes projects focused on early cancer detection, recurrence monitoring, and assessing minimal residual disease. The company collaborates with leading academic institutions, biopharmaceutical companies, and researchers to further advance the field of precision medicine.
Guardant Health's mission is to transform cancer care by utilizing innovative technologies and data-driven insights to improve patient outcomes. Their advanced diagnostic solutions empower physicians with actionable genomic information, helping them make more informed treatment decisions and ultimately contributing to the effort of fighting cancer.